Last updated on January 2017

Stem Cell Ophthalmology Treatment Study II


Brief description of study

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Detailed Study Description

Eyes with loss of vision from retinal or optic nerve conditions generally considered irreversible will be treated with a combination of injections of autologous bone marrow derived stem cells isolated from the bone marrow using standard medical and surgical practices. Retinal conditions may include degenerative, ischemic or physical damage ( examples may include macular degeneration, hereditary retinal dystrophies such as retinitis pigmentosa, stargardt, non-perfusion retinopathies, post retinal detachment. Optic Nerve conditions may include degenerative, ischemic or physical damage ( examples may include optic nerve damage from glaucoma, compression, ischemic optic neuropathy, optic atrophy ). Injections may include retrobulbar, subtenon, intravitreal, intraocular, subretinal and intravenous. Patients will be followed for 12 months with serial comprehensive eye examinations including relevant imaging and diagnostic ophthalmic testing.

Clinical Study Identifier: NCT03011541

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jeffrey N Weiss, MD

The Healing Institute
Margate, FL United States
  Connect »

Steven Levy, MD

Al Zahra Hospital
Dubai, United Arab Emirates
  Connect »